TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03142165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: 3 weekly doses of 90 mg infused intravenous administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 50 mg intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: 50 mg intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 20 mg intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Famotidine
Description: 20 mg intravenous administration
Study: NCT04553146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implantation in posterior region with alveolar ridge preservation combined with sealing socket abutment
Description: Twenty BLXⓇ Straumann immediate implants were placed flapless. The gap around the implant was filled with xenogeneic biomaterial. An intra-oral scanner was performed and sent to the dental laboratory to digitally design a customized healing abutment. The abutment was then milled from a block of PEEK and placed a couple of hours later in the clinic. Three months after implantation, the abutment was removed and the final monolithic crown based on the initial IOS was placed. The transmucosal design from the SSA was replicated on the final crown.
Study: NCT01997372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: Drug ATG:2.5mg/kg/d or 3.75mg/kg/d for 5 days; Drug Cyclosporine A (CSA):3-10mg/kg/d ,Adjust the dose to maintain drug levels between 150 and 300ng/ml; Drug prednisone:1mg/kg/d,d1-21 from the first dosage of ATG; Drug Granulocyte Colony-Stimulating Factor(G-CSF):5ug/kg/d until absolute neutrophil count (ANC) \>1×109/L.
Study: NCT01268787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Description: Two-vaccination 0.25ml or 0.5ml dose assigned to two groups.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 vaccine
Description: Two-vaccination 0.25ml or 0.5ml dose assigned to two groups.
Study: NCT00873093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 and 9
Study: NCT00726557

Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered at 10.6 mg/kg/day for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue Rebetol therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
Study: NCT00873093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO or IV 40 mg/m2/day on Days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO or IV 40 mg/m2/day on Days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO or IV 40 mg/m2/day on Days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO or IV 40 mg/m2/day on Days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO or IV 40 mg/m2/day on Days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 and 11 Block 2: Days 1, 4 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 and 11 Block 2: Days 1, 4 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 and 11 Block 2: Days 1, 4 and 8
Study: NCT02582177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canesten®
Description: Apply on the affected area and around it twice a day
Study: NCT04161768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin
Description: Norfloxacin 400 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Description: Norfloxacin 400 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride
Description: Itopride 50 mg three times daily
Study: NCT04518956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inter maxillary fixation with shockwave therapy
Description: Shockwave therapy device which give 1500-4000 pulses per session with or without anesthesia, and the treatment session takes approximately 5-10 minutes at the day after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inter maxillary fixation and exposure to low intensity pulsed
Description: Low-intensity pulsed ultra sound was applied three times weekly for six weeks from the second day after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inter maxillary fixation
Description: Closed reduction will be done. Intermaxillary fixation (IMF) will be secured after proper reduction of the fractured segments to assure proper occlusion using upper and lower arch bars or eyelet wires for six weeks.
Study: NCT04550013

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heavy-Slow Resistance training
Description: Resistance training for knee extensors. The exercise will be performed at 80% of 1 RM and slowly (6 s/repetition).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Load Blood Flow Restriction training
Description: Resistance training for knee extensors. The exercise will be performed at 30% of 1 RM and with a relative Artery Occlusion Pressure of 80%
Study: NCT02124122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Probiotic

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02895763

Intervention type: OTHER
Intervention: Form administrations
Study: NCT02193893

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biological: Cell-based therapeutics
Description: Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.
Study: NCT03281135

Intervention type: OTHER
Group type: OTHER
Intervention: HPV testing
Description: Clusters randomly allocated to this arm of the study will be sensitized to be showed up in nearby health posts for self sampling with Evalyn brush for HPV testing.
Study: NCT04542356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: During the concurrent chemoradiotherapy, a single subcutaneous injection of 6 mg PEG-rhG-CSF was given to the patient 2 hours after radiotherapy on the first day after the end of chemotherapy. Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rhG-CSF
Description: Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
Study: NCT03977129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QFR-guided strategy
Description: In this study, the QFR-guided strategy will be applied to in the QFR group in which calculation of the QFR values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to CABG revascularization will be carried out. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR \> 0.80, then no CABG revascularization of target blood vessels will be carried out.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAG-guided strategy
Description: In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and suited for CABG revascularization will undergo CABG revascularization.
Study: NCT00873093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 and 11 Block 2: Days 1, 4 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 and 11 Block 2: Days 1, 4 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 and 22
Study: NCT04004676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 20 km time trial performance
Description: 20 km time trial cycling test will be conducted to measure the effect of different drinks on performance time

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 20 km time trial performance
Description: 20 km time trial cycling test will be conducted to measure the effect of different drinks on performance time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glycogen lowering exercise
Description: Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Glycogen lowering exercise
Description: Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
Study: NCT00873093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22
Study: NCT00445445

Intervention type: OTHER
Intervention: physiologic testing
Description: Urine samples will be assessed for levels of bisphenol-A
Study: NCT02193893

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Symptomatic treatment of ALS
Description: Symptomatic neurological treatment of ALS
Study: NCT00445445

Intervention type: OTHER
Intervention: physiologic testing
Description: Urine samples will be assessed for levels of bisphenol-A

Intervention type: OTHER
Intervention: screening questionnaire administration
Description: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
Study: NCT03988647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered at 200 mg IV every 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 9 Gy X 3 (27 Gy in 3 fractions), or 4-6 Gy X 5 (20-30 Gy in 5 fractions).
Study: NCT02057991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Watch an educational video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Watch an educational video

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAM exercise therapy
Description: Watch a mindfulness exercise video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caregiver-related intervention or procedure
Description: Watch mindfulness exercise video and/or educational video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caregiver-related intervention or procedure
Description: Watch mindfulness exercise video and/or educational video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00694343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (6%) in sodium chloride (solution for infusion)
Description: 500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate solution
Description: 1000 mL Ringer's Lactate solution
Study: NCT02702310

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: At initial visit (day 1) - for determination of a baseline quality of life, patients will be given a self-reported questionnaire called the Skindex-29. Following standard of care radiation treatments, at weeks 6 \& 12, and every 3 months thereafter, patients will complete the Skindex-29 questionnaire.

Intervention type: OTHER
Intervention: Objective Grading of Skin Findings
Description: At initial visit (day 1) , using mSWAT the radiation oncologist can follow the patient's treatment response by accurately grading the severity of the patient's skin findings. Following standard of care radiation treatments, at weeks 6 \& 12, and every 3 months thereafter, mSWAT will again be determined by physician. Follow-up visits will continue until patient has a change in disease.
Study: NCT04303923

Intervention type: PROCEDURE
Intervention: Ultrasonography
Description: The diameters of both the radial artery and the distal radial artery were measured by ultrasonography.

Intervention type: PROCEDURE
Intervention: Ultrasonography
Description: The diameters of both the radial artery and the distal radial artery were measured by ultrasonography.
Study: NCT01120067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Treatment
Description: Participants randomized to the Intensive Treatment condition will attend 6 bi-weekly outpatient therapy sessions conducted in an individual format of 90 minutes in duration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as Usual.
Study: NCT03761797

Intervention type: DRUG
Intervention: TRADIANCE® Combination Tablets AP
Description: Fixed dose combination

Intervention type: DRUG
Intervention: TRADIANCE® Combination Tablets BP
Description: Fixed dose combination
Study: NCT04032574

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Herbal Medicinal Product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03872011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C,thiamine,hydrocortisone
Description: Vitamin C (2g) will be diluted in 100ml 0.9%NACL and administered ivd every 6 hours for 5 days or until participant is discharged from the ICU.~Thiamine(200mg) will be diluted in 100ml 0.9%NACL and administered ivd every 12 hours for 5 days or until participant is discharged from the ICU. Hydrocortisone was administered 200 mg/d as a continuous infusion for 5 days or until participant is discharged from the ICU.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% NaCl solution) volume to match all components
Study: NCT02739737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blinded manuscript
Description: Blinded version of sham manuscript

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unblinded manuscript
Description: Unblinded version of sham manuscript
Study: NCT03120988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lavage with Platelet Poor Plasma (PPP)
Description: Lavage of 50cc PPP
Study: NCT05245279

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3 dimensional ultrasound investigation
Description: Images that contributed to the determination of placental volume and 3-DPD indices were obtained at the time of visit. All 3-D scans ultrasound measurements were performed by a Voluson 730 Expert ultrasound machine equipped with a multifrequency probe (2-5 MHz) to acquire images. Each sample was examined using 3-D rendering mode, in which the colour and gray value information was processed and combined to supply 3-D image. For laterally located placentas, the investigator positioned the transducer on a slight lateral inclination to obtain proper images. Power Doppler window was placed over the placenta to map the vascular tree from basal to chorionic plates. The 3-D static volume box was placed over the entire placenta volume. The sweep angle was set at maximum 70°. Each image was recovered from the disk in succession for processing. During gestation, the investigator recorded one sample from each patient.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3 dimensional ultrasound investigation
Description: Images that contributed to the determination of placental volume and 3-DPD indices were obtained at the time of visit. All 3-D scans ultrasound measurements were performed by a Voluson 730 Expert ultrasound machine equipped with a multifrequency probe (2-5 MHz) to acquire images. Each sample was examined using 3-D rendering mode, in which the colour and gray value information was processed and combined to supply 3-D image. For laterally located placentas, the investigator positioned the transducer on a slight lateral inclination to obtain proper images. Power Doppler window was placed over the placenta to map the vascular tree from basal to chorionic plates. The 3-D static volume box was placed over the entire placenta volume. The sweep angle was set at maximum 70°. Each image was recovered from the disk in succession for processing. During gestation, the investigator recorded one sample from each patient.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2 dimensional ultrasound investigation
Description: The two-dimensional (2-D) transabdominal conventional study provided data about fetal position, biometry, body movements and fetal heart rate as well as placental localization. The factorial default setting 'Obstetrics' was applied in 2-D mode.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2 dimensional ultrasound investigation
Description: The two-dimensional (2-D) transabdominal conventional study provided data about fetal position, biometry, body movements and fetal heart rate as well as placental localization. The factorial default setting 'Obstetrics' was applied in 2-D mode.
Study: NCT01551940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox injection
Description: Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.